Skip to main content

Table 6 Effect of EMZSB on blood glucose level in alloxan-induced diabetic rats

From: Screening of Manilkara zapota (L) P. Royen stem bark ethanolic extract for in vitro α-glucosidase inhibition, preliminary antidiabetic effects, and improvement of diabetes and its complications in alloxan-induced diabetes in Wistar rats

Groups

Blood glucose level (mg dl−1) at

1st day

7th day

14th day

21st day

Normal control

70.36 ± 3.46

72.57 ± 4.55

74.81 ± 3.58

72.67 ± 4.29

Diabetic control

245.58 ± 9.58$

258.85 ± 10.59$

265.98 ± 12.58$

270.29 ± 10.67$

Diabetic + Glimepiride

265.85 ± 10.98

234.28 ± 8.75

205.58 ± 11.65**

186.68 ± 12.34***

Diabetic + EMZSB 150

259.58 ± 7.64

249.74 ± 12.58

243.98 ± 7.38

233.87 ± 8.74

Diabetic + EMZSB 200

258.64 ± 11.47

245.75 ± 10.48

239.67 ± 10.53

214.52 ± 8.75*

Diabetic + EMZSB 250

255.52 ± 12.53

242.68 ± 10.31

219.42 ± 8.78

198.68 ± 9.52**

  1. Values were presented as mean ± SEM (n = 6); statistics employed was two-way ANOVA followed by Tukey’s multiple comparison test. Diabetic animals when treated with EMZSB 250 showed a significant (p < 0.01) reduction in the blood glucose levels on 21st day. $p < 0.001
  2. When compared with diabetic control; *p < 0.05, **p < 0.01, and ***p < 0.001